IP Library › Granted Patent US 8,158,579
Granted Patent B2
US 8,158,579 · App. 12/956,623 · Granted Apr 17, 2012

Fusion protein of an exendin to modified transferrin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,579
App. No.
12/956,623
Granted
Apr 17, 2012
Kind
B2
Abstract

The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.

Claims (5)

1. A fusion protein comprising an exendin-4 fused to a modified transferrin (mTf), wherein said fusion protein comprises the amino acid sequence as shown in SEQ ID NO: 23.

2. A pharmaceutical composition comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , wherein the composition is adapted to be administered at a dose ranging from 0.5 mg to 50 mg.

4. The pharmaceutical composition of claim 2 , wherein the composition is adapted to be administered at a dose of 1 mg to 100 mg.

5. The pharmaceutical composition of claim 2 , wherein the composition is adapted to be administered via inhalation.